三生国健: 三生国健：关于将部分项目节余资金用于暂时补充流动资金以及调整部分募投项目拟投入募集资金金额的公告

Core Viewpoint - Sangfor Health plans to temporarily use surplus funds from several projects to supplement working capital and adjust the investment amounts for certain fundraising projects [1][12]. Fundraising Basic Situation - The company was approved to publicly issue 61,621,142 shares at a price of RMB 28.18 per share, raising a total of approximately RMB 1.736 billion, with a net amount of about RMB 1.634 billion after deducting fees [2][3]. Adjustments to Fundraising Projects - The company intends to reduce the investment amount for the "Innovative Antibody Drug Industrialization and Digital Factory Construction Project" from RMB 400 million to RMB 320 million, a reduction of RMB 80 million [1][6]. - The investment for the "Self-immune and Ophthalmic Disease Antibody Drug New Drug R&D Project" will be increased from RMB 610 million to RMB 690 million [1][6]. Surplus Fund Usage Plan - As of April 30, 2025, surplus funds from completed projects will be used to temporarily supplement working capital, amounting to RMB 66.6282 million [4][10]. - The surplus funds will be transferred to the "Supplementary Working Capital Project" account, with a usage period not exceeding 12 months from the date of shareholder meeting approval [4][10]. Reasons for Adjustments - The adjustments are made to enhance the efficiency of fund usage and align with the company's strategic focus on self-immune diseases and inflammation, which have significant unmet clinical needs [6][10]. - The company has shifted focus from certain oncology projects to prioritize self-immune disease projects, reflecting changes in market conditions [4][10]. Board and Supervisory Committee Approval - The board of directors and the supervisory committee have both approved the proposal to use surplus funds for working capital and adjust project investments, emphasizing that these actions will not harm the interests of shareholders [11][12].